X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Fresenius Kabi Onco. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs FRESENIUS KABI ONCO. - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS FRESENIUS KABI ONCO. IPCA LABS/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 45.2 22.1 204.4% View Chart
P/BV x 3.5 3.1 111.5% View Chart
Dividend Yield % 0.1 0.0 -  

Financials

 IPCA LABS   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    IPCA LABS
Mar-17
FRESENIUS KABI ONCO.
Mar-13
IPCA LABS/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs643176 365.3%   
Low Rs50379 640.5%   
Sales per share (Unadj.) Rs254.437.7 675.1%  
Earnings per share (Unadj.) Rs16.15.1 315.5%  
Cash flow per share (Unadj.) Rs29.86.7 442.9%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs194.642.5 457.3%  
Shares outstanding (eoy) m126.20158.23 79.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.33.4 66.7%   
Avg P/E ratio x35.725.0 142.7%  
P/CF ratio (eoy) x19.218.9 101.7%  
Price / Book Value ratio x2.93.0 98.5%  
Dividend payout %6.20-   
Avg Mkt Cap Rs m72,30020,135 359.1%   
No. of employees `00013.31.2 1,154.8%   
Total wages/salary Rs m6,960703 989.7%   
Avg. sales/employee Rs Th2,413.55,176.2 46.6%   
Avg. wages/employee Rs Th523.2610.4 85.7%   
Avg. net profit/employee Rs Th152.4699.6 21.8%   
INCOME DATA
Net Sales Rs m32,1065,963 538.4%  
Other income Rs m22618 1,253.9%   
Total revenues Rs m32,3325,981 540.6%   
Gross profit Rs m4,4481,430 311.0%  
Depreciation Rs m1,730258 670.6%   
Interest Rs m241-26 -926.2%   
Profit before tax Rs m2,7031,216 222.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m675342 197.3%   
Profit after tax Rs m2,028806 251.6%  
Gross profit margin %13.924.0 57.8%  
Effective tax rate %25.028.1 88.8%   
Net profit margin %6.313.5 46.7%  
BALANCE SHEET DATA
Current assets Rs m17,3405,102 339.9%   
Current liabilities Rs m9,5592,385 400.7%   
Net working cap to sales %24.245.6 53.2%  
Current ratio x1.82.1 84.8%  
Inventory Days Days100150 66.9%  
Debtors Days Days57113 50.2%  
Net fixed assets Rs m20,7795,148 403.6%   
Share capital Rs m252158 159.5%   
"Free" reserves Rs m24,4996,556 373.7%   
Net worth Rs m24,5536,732 364.7%   
Long term debt Rs m3,517952 369.4%   
Total assets Rs m39,59510,388 381.2%  
Interest coverage x12.2-45.8 -26.7%   
Debt to equity ratio x0.10.1 101.3%  
Sales to assets ratio x0.80.6 141.3%   
Return on assets %5.77.5 76.3%  
Return on equity %8.312.0 69.0%  
Return on capital %10.514.6 71.8%  
Exports to sales %48.674.5 65.3%   
Imports to sales %14.224.8 57.5%   
Exports (fob) Rs m15,6174,441 351.7%   
Imports (cif) Rs m4,5711,477 309.4%   
Fx inflow Rs m15,6175,298 294.8%   
Fx outflow Rs m5,8281,772 328.8%   
Net fx Rs m9,7903,525 277.7%   
CASH FLOW
From Operations Rs m2,7641,274 217.0%  
From Investments Rs m-1,432-1,204 118.9%  
From Financial Activity Rs m-1,591-196 811.5%  
Net Cashflow Rs m-259-126 204.9%  

Share Holding

Indian Promoters % 45.9 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 11.4 0.3 3,800.0%  
FIIs % 25.3 9.6 263.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 9.1 191.2%  
Shareholders   36,892 42,599 86.6%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   SANOFI INDIA  TORRENT PHARMA  PLETHICO PHARMA  WYETH LTD  ABBOTT INDIA  

Compare IPCA LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Rising Dollar after Fed Minutes; F&O Expiry and Top Stocks in Action Today(Pre-Open)

Indian share markets ended largely flat on Thursday following the expiry of derivative contracts for February series. The S&P BSE Sensex ended down by 25 points.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Feb 23, 2018 09:31 AM

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - FRESENIUS KABI ONCO. COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS